Fran García Verdejo

Oncólogo médico. Hospital Universitario de Jaén. Hospital Vithas de Granada.

[Ana Fernández Montes, MD,Phd @afm1003]

Un honor haber coordinado con mi compañera y amiga, Beatriz Gonzalez Astorga estas jornadas de formación #empowerGi @UAHes @EspanaServier

[Yüksel Ürün @DrYukselUrun]

🌟🧬🧬🎯 Tumor-agnostic therapies are revolutionizing oncology! Instead of focusing on tumor origin, these treatments target specific genetic anomalies driving cancer growth.
@CACancerJournal
@ASCO @oncoalert @VivekSubbiah @BurrisSkip @Dr_R_Kurzrock @isliquidbiopsy @EricTopol
#Oncology #CancerTreatment #TumorAgnostic #PrecisionMedicine #CancerResearch
https://t.co/Z7grpHECjz

[Dr. Cathy Eng @CathyEngMD]

🤩 @VanMorrisMD @MDAndersonNews presents on the role of #HPV #ctDNA as prognostic marker at 3M after chemoXRT for #analcancer re: RFS.

#ancsm #cancer #cancerresearch #ASCO24 @ASCO @HPVAlliance @HPVAnalCancer

[OncLive.com @OncLive]

Excellent session by Christopher booth in @csoncol

[Myriam Chalabi @MyriamChalabi]

👏👏👏👏 #NADINA
- Neoadj 2 cycles of ipi/nivo is better than adj 12x nivo!
- pts with MPR did not receive adj IO: these pts did even better!
- now we have to make this standard of care!!!
@ProfGLongMIA @ProfCUBlankNKI @NKI_nl @ASCOPost

[Arndt Vogel @ArndtVogel]

Efficacy of etrumadenant (increases Adenosin) & zimberelimab (anti-PD) vs Regorafenib in previously treated mCRC
🔎 ARC-9 phs-2, 112 pts
👉ORR 17 vs 2%
👉mPFS 6.2 vs 2.1 mo, HR 027
👉mOS 19.7 vs 9.5 mo
🧐Longest OS in 3rd line so far reported, meaningful improvements
@myESMO

[Arndt Vogel @ArndtVogel]

🔥PLENARY Session #ASCO24🔥
Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus
🔎 ESOPEC phase III trial, 438 patients
👉R0 180 vs 171
👉pCR 17 vs 10%
👉mOS 66 vs 37 mo
👉3yr OS: 57.4 vs 50.7%
🧐FLOT improves OS compared to CROSS
@myESMO

[Dr Amol Akhade @SuyogCancer]

ADRIATIC trial . Durvalumab for 2 years consolidation for limited stage SCLC shows OS and PFS benifit.

This should be standard of care . @ASCO @brunolarvol @Larvol

[Abeid Athman (Omar). @bin_abeid]

Adjuvant Osimertinib showed superior survival than placebo in unresectable Stage III EGFR driven lung cancer compared to the placebo according to the LAURA trial. The curves separation are shouting 😎😉#ASCO24 @OncoAlert @HamidMD10 @StephenVLiu

[Arndt Vogel @ArndtVogel]

Neoadjuvant pembrolizumab stratified to TMB for high risk stage 2 or stage 3 MSI-high CRC #ASCO24
🔎NEOPRISM-CRC, 32 pts
👉only 1 TMB-low
👉62% rT1a/b
👉pCR: 59%
👉No relapse
🧐safe & effective, translational program awaited
@myESMO

[Mark Lewis, MD, FASCO @marklewismd]

Over the last 15 years, has anyone done more than Dr. Jennifer Temel to foreground the beneficial co-existence of palliative care & oncology services?! 🤩 (And yet we still have to convince our patients -- and some colleagues -- that PC is not synonymous with hospice) #ASCO24

[GEICAM - Cáncer de mama @GEICAM]

Nuestro investigador @anderu71 nos traslada desde #Chicago los resultados, y sus implicaciones, de nuestro registro de #cáncerdemama en el varón que hemos presentado hoy en #ASCO24 #SomosGEICAM

[Fran García Verdejo @FranGVerdejo]

I encuentro de cortadores solidarios de Jaén.
+70 cortadores
Beneficio a la asociación A.L.E.S

[Vinay Mathew Thomas @vinay_onc]

🔥 Our viewpoint article on CheckMate 901 is now out in @MedCellPress. We discuss its findings, how they relate to EV-302, & the importance of personalized treatment. Grateful to mentorship by @neerajaiims and @PGrivasMDPhD! Link to full article 👉 https://t.co/pmsjWHEWpN

[EFEsalud @efesalud]

Los nuevos casos de #cáncer alcanzarán en 2024 los 286.664, un 2,6 % más que en 2023, según el informe de @_SEOM "Las cifras del cáncer en España".
Los más frecuentes, colon y recto, mama y pulmón.
#EjercicioVsCáncer  #DiaMundialContraElCancer 
https://t.co/tnx55hy2zV

[GranadaDigital @granadadigital]

🏥👩‍⚕️ #Salud | Especialistas de @Vithas #Andalucía recalcan la importancia de la prevención en el Día Mundial contra el Cáncer.

👩‍⚕️ La evidencia científica remarca la importancia de los cribados para salvar vidas.

Puedes leer más aquí 👇

https://t.co/SotooO3Pjb

[SEOM @_SEOM]

El ejercicio físico puede reducir hasta un 30% el riesgo de muchos tipos de cáncer como los de mama, colon, vejiga, endometrio, esófago y estómago, y en casi el 20% el riesgo de mortalidad específica por cáncer #EjercicioVsCáncer #DMCáncer24

[Fran García Verdejo @FranGVerdejo]

@jarranza 🔝¡Efectivamente! 11 ensayos clínicos que “darán forma” a la medicina en 2024 según la prestigiosa revista @NatureMedicine y 2 de #IA (uno de IA en cáncer).

[Toni Choueiri, MD @DrChoueiri]

51 years in the making till #GU24. OS benefit in adjuvant Renal Cancer is finally here. #KYN564

[Toni Choueiri, MD @DrChoueiri]

And now @MichvdHeijden reporting results of the Subgroup analyses from EV-302 initially presented @ESMO @tompowles OS benefit was consitently observed across select prespecified subgroups, including those historically associated with poor prognosis @ASCO #GU24
@OncoAlert